Home Cart Sign in  
Chemical Structure| 133865-89-1 Chemical Structure| 133865-89-1

Structure of Safinamide
CAS No.: 133865-89-1

Chemical Structure| 133865-89-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Safinamide is a reversible and highly selective MAO-B inhibitor with IC50 of 98 nM.

Synonyms: FCE 26743; EMD 1195686; PNU-15774E

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Safinamide

CAS No. :133865-89-1
Formula : C17H19FN2O2
M.W : 302.34
SMILES Code : C[C@H](NCC1=CC=C(OCC2=CC=CC(F)=C2)C=C1)C(N)=O
Synonyms :
FCE 26743; EMD 1195686; PNU-15774E
MDL No. :MFCD00897036
InChI Key :NEMGRZFTLSKBAP-LBPRGKRZSA-N
Pubchem ID :131682

Safety of Safinamide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H319
Precautionary Statements:P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • MAO-B

    MAO-B, IC50:98 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00627640 Idiopathic Parkinson's Disease Phase 3 Completed - -
NCT00642889 Parkinson's Disease Phase 3 Completed - -
NCT01028586 Idiopathic Parkinson's Disease Phase 3 Terminated(Trial is terminated... More >> due to a company decision to return all rights for Safinamide back to Newron Pharmaceuticals) Less << - Switzerland ... More >> Enquire Central Contact Geneva, Switzerland Less <<
NCT01187966 Parkinson's Disease Phase 3 Completed - -
NCT01286935 Parkinson's Disease Phase 3 Completed - -
NCT03648671 - Recruiting November 30, 2019 Italy ... More >> Azienda ospedaliera universitaria integrata verona Recruiting Verona, Italy, 37126 Contact: Michele Tinazzi, MD, PhD    0458027472    michele.tinazzi@univr.it Less <<
NCT00865579 Parkinson's Disease PHASE3 TERMINATED 2025-06-12 Research Site, Timis, Romania
NCT00605683 Idiopathic Parkinson's Disease Phase 3 Completed - -
NCT00643045 Idiopathic Parkinson's Disease Phase 3 Completed - -
NCT01026428 Idiopathic Parkinson's Disease Phase 1 Phase 2 Completed - Italy ... More >> Research Site Casino, Italy Research Site Roma, Italy Less <<
NCT01027169 Hepatic Impairment Phase 1 Completed - Germany ... More >> CRS Clinical Research Services Kiel GmbH Kiel, Germany Less <<
NCT03753763 Multiple System Atrophy Phase 2 Not yet recruiting March 31, 2020 -
NCT01264861 Parkinson Disease PHASE2 TERMINATED 2012-01-24 Molecular Neuroimaging, LLC, N... More >>ew Haven, Connecticut, 06510, United States Less <<
NCT02495831 Healthy Phase 1 Completed - Switzerland ... More >> Cross Research SA, Phase I Unit Arzo, Ticino, Switzerland, 6864 Less <<
NCT01211587 Parkinson's Disease With Cogni... More >>tive Impairments Less << Phase 2 Completed - United States, California ... More >> The Parkinson's Institute Sunnyvale, California, United States United States, Florida Mayo Clinic Florida Jacksonville, Florida, United States United States, Georgia Emory University Atlanta, Georgia, United States United States, Illinois Northwestern University Chicago, Illinois, United States Rush University Medical Center Chicago, Illinois, United States United States, Maryland Johns Hopkins University Baltimore, Maryland, United States United States, Massachusetts US Medical Information Located in Rockland, Massachusetts, United States United States, Ohio Cleveland Clinic Cleveland, Ohio, United States United States, Texas Baylor College of Medicine Parkinson's Disease Center and Movement Disorders Clinic Houston, Texas, United States Spain Hospital Clinic de Barcelona Barcelona, Spain Hospital De La Santa Creui Sant Pau Barcelona, Spain Hospital General de Catalunya Barcelona, Spain USP Institut Universitari Dexeus Barcelona, Spain Hosptial General Univ Gregorio Maranon Madrid, Spain Hospital Mutual de Terrassa Terrassa - Barcelona, Spain Less <<
NCT03216304 Healthy Phase 1 Completed - Switzerland ... More >> CROSS Research SA, Phase I Unit Arzo, Ticino, Switzerland, 6864 Less <<
NCT02495831 - Completed - -
NCT01113320 Parkinson's Disease Phase 2 Completed - Austria ... More >> Medical University Graz, Klinische Abteilung für Spezielle Neurologie Graz, Austria Medical University Innsbruck, Dept. of Neurology Innsbruck, Austria Canada Quebec Memory and Motor Skills Disorders Quebec, Canada France Hôpital Roger Sallengro Lille, France CIC-Hospital Purpan Toulouse, France Germany Neurologie Berlin Praxen Berlin, Germany St. Josef Hospital, Klinik für Neurologie Bochum, Germany Facharzt für Neurologie und Psychiatrie Düsseldorf, Germany South Africa Medical and Dental center (ZAF) Johannesbourg, South Africa Sunninghill Hospital Johannesburg, South Africa Willows Medical Centre Pretoria, South Africa Less <<
NCT01374113 Renal Impairment Phase 1 Completed - Germany ... More >> CRS Clinical Research Services Kiel GmbH Kiel, Schleswig-Holstein, Germany Less <<
NCT03843944 Parkinson Disease PHASE4 COMPLETED 2019-05-31 IRCCS San Raffaele, Roma, 0016... More >>3, Italy Less <<
NCT03968744 Idiopathic Parkinson's Disease... More >> (at Later Stage) Less << PHASE4 RECRUITING 2025-04-30 Neurocenter of Southern Switze... More >>rland - Ente Ospedaliero Cantonale (EOC), Lugano, 6900, Switzerland Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.31mL

0.66mL

0.33mL

16.54mL

3.31mL

1.65mL

33.08mL

6.62mL

3.31mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories